NCT03104634View on ClinicalTrials.gov

The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

December 1, 2018

Study Completion Date

February 1, 2019

Conditions
Smoking
Interventions
DRUG

Aclidinium bromide/formoterol fumarate dihydrate

Cross-over design with washout interval. Randomized order of active and placebo arm

DRUG

Placebo

Placebo and delivery device matched to active intervention

Trial Locations (1)

H4A 3J1

McGill University Health Centre Research Institute, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT03104634 - The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers | Biotech Hunter | Biotech Hunter